NCT06945666View on ClinicalTrials.gov

A Study of Iguratimod in Combination With Tofacitinib in RA Patients

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

August 1, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

May 31, 2027

Conditions
Rheumatoid Arthritis (RA
Interventions
DRUG

Combined therapy of Iguratimod and tofacitinib

This study aims to evaluate the efficacy and safety of the combination of iguratimod and tofacitinib in the treatment of RA patients with poor responses to traditional or biological DMARDs, providing evidence-based support for clinical treatment.

Trial Locations (1)

322000

4th Affiliated Hospital, School of Medicine, Zhejiang University, Yiwu

All Listed Sponsors
lead

Jie Chang

OTHER